Bristol goes pivotal with SystImmune-partnered conjugate
The first global pivotal trial will be in first-line triple-negative breast cancer.
RemeGen cools on DR5
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
Telix sees more backing for LAT1
TLX101 follows Ipax-1 with an apparent success in an academic trial.
Mural hits a wall
The company scraps nemvaleukin after the latest failure, of Artistry-6.
J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
